Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

Inclusion Criteria: * Signed informed consent before initiation of any study-related procedure and agreement to comply with all protocol-specific procedures * Stable angina pectoris (CCS Class 1, 2, 3, 4) or unstable angina (Braundwald class 1-3, B) or documented silent ischemia * Baseline ECG with stable sinus rhythm and no signs of ischemia and with no Q waves, bundle branch block or IV conduction disturbances. * Normal left ventricular wall motion on left ventricular angiogram or on echocardiogram with preserved systolic global LV function * Non-occlusive stenosis, located in the proximal segments of the left anterior descending artery (LAD) (segments 6 and/or 7) and/or circumflex artery (CFX) (segments 11 and/or 12) or right coronary artery (RCA) (segments 1, 2 and/or 3) for which there is clinical indication to percutaneous treatment with coronary stenting * Successful PCI with stenting on the target vessel * Older than 18 years and younger than 80 years of age Exclusion Criteria: * Active ischemia at the initiation of the study procedure * Non-ST segment elevation myocardial infarction * History or ECG evidence of prior MI in the territory supplied by the vessel undergoing PCI, IV conduction defects/baseline ST-segment abnormalities on the surface ECG * Moderate to severe aortic or mitral valve disease * Evidence of LV hypertrophy on the echocardiogram IVS \> 13 and/or PW \> 13mm * Angiographically visible collateral vessels to the target vessel * Hypertension not adequately controlled by anti-hypertensive therapy at the time of study entry (\> 140/100mmHg) * Uncompensated congestive heart failure or signs of pulmonary edema * Significant hemodynamic compromise and/or cardiogenic shock requiring inotropic or pressor support * Contraindications to standard drugs for coronary intervention and coronary heart disease: aspirin, heparin, low molecular weight heparin, clopidogrel, contrast dye * Confirmed pregnancy * Systemic mastocytosis * Hypoxemia (need for mechanical ventilation * Known history of COPD with FEV 1s \< 1.0 liter * Renal impairment: creatinine \> 1.6 mg/dl * Participation in another trial with an investigational drug or device including follow-up period, within the last 30 days before enrollment Additional exclusion criteria at the end of PCI (before randomization) * Coronary TIMI flow in the treated artery is less than 3 * Serious arrhythmias during/following the PCI was noted * Coronary spasm following PCI * Any deterioration in the subject's "risk" status between informed consent and randomization